文献速递膀胱癌与上尿路尿路上皮癌

高危T1期膀胱癌初始治疗:膀胱内卡介苗与即刻根治性膀胱切除术的成本-效用分析

Cost-utility of Initial Management of High-grade T1 Bladder Cancer With Intravesical BCG vs Immediate Radical Cystectomy.
PubMed 文献 · Urology · 2024-03-11

该研究采用决策分析马尔可夫模型,比较高危T1期非肌层浸润性膀胱癌分别以膀胱内卡介苗(BCG)与即刻根治性膀胱切除术联合回肠导管尿流改道作为初始管理的成本-效用。平均费用BCG组为26093美元,即刻膀胱切除术组为39720美元,后者额外获得2.2个质量调整生命年(QALY),增量成本-效用比为7120美元/QALY。作者结论为在当前价格下,早期根治性膀胱切除术是更具成本-效用的管理策略。

要点

  • 即刻根治性膀胱切除术较膀胱内BCG多获得2.2个QALY,增量成本-效用比为7120美元/QALY。
  • 若高危T1期5年复发率低于56%或5年进展至肌层浸润性膀胱癌率低于4%,膀胱内BCG即成为具成本-效用的策略。
  • 膀胱切除术、经尿道膀胱肿瘤电切术(TURBT)及BCG毒性的费用对增量成本-效用比影响最大。

核心结论

  • 在当前价格下,对高危T1期非肌层浸润性膀胱癌采用早期根治性膀胱切除术,比初始采用膀胱内BCG是更具成本-效用的管理策略。

研究设计与样本

  • 采用决策分析马尔可夫模型,比较高危T1期非肌层浸润性膀胱癌以膀胱内BCG与早期根治性膀胱切除术联合回肠导管尿流改道进行初始管理的成本-效用。
  • 从文献中提取5年肿瘤学结局、不良事件发生率及已发表的效用值。
  • 费用从美国医疗保险(Medicare)角度按2021年美元计算。
  • 通过敏感性分析确定费用驱动因素及复发与进展的盈亏平衡点。

主要发现

  • 平均费用膀胱内BCG组为26093美元,即刻根治性膀胱切除术组为39720美元,即刻根治性膀胱切除术较膀胱内BCG多获得2.2个质量调整生命年(QALY)。
  • 即刻根治性膀胱切除术治疗高危T1期非肌层浸润性膀胱癌的增量成本-效用比(ICER)为7120美元/QALY。
  • 膀胱切除术、经尿道膀胱肿瘤电切术(TURBT)及BCG毒性相关费用对ICER影响最大。
  • 单因素敏感性分析显示,若高危T1期5年复发率低于56%或5年进展至肌层浸润性膀胱癌率低于4%,膀胱内BCG即成为具成本-效用的管理策略。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the cost-utility of initial management of high-grade T1 non-muscle invasive bladder cancer (HGT1 NMIBC) with intravesical BCG vs immediate radical cystectomy. High-risk NMIBC patients may climb a costly ladder of treatments, culminating in radical cystectomy for oncologic or symptomatic benefit in up to one-third. This high healthcare resource utilization presents a challenging dilemma in balancing sufficiently aggressive management with cost, toxicity, and quality-of-life. METHODS: Cost-utility of initially managing HGT1 with intravesical BCG and early radical cystectomy with ileal conduit urinary diversion was compared using decision-analytic Markov models. Five-year oncologic outcomes, adverse event rates, and published utility values were extracted from literature. Costs were calculated from a US Medicare perspective in 2021 US dollars. Sensitivity analysis identified drivers of cost and break-even points for recurrence and progression. RESULTS: Mean costs were $26,093 for intravesical BCG and $39,720 for immediate radical cystectomy, though cystectomy generated a gain of 2.2 quality-adjusted life years (QALYs) compared to intravesical BCG. Immediate cystectomy was a more cost-effective management strategy for HGT1 NMIBC with an incremental CE ratios (ICER) of $7120/QALY. The costs associated with cystectomy, TURBT, and BCG toxicity had the greatest impact on ICER. One-way sensitivity analysis demonstrated that intravesical BCG became a cost-effective management strategy if the 5-year recurrence rate of HG T1 was less than 56% or the 5-year progression rate to MIBC was less than 4%. CONCLUSION: At current prices, treatment of high-grade T1 NMIBC with early radical cystectomy is more cost-effective management strategy than initial treatment with intravesical BCG.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Huelster HL, Mason NT, Davaro F, et al. Cost-utility of Initial Management of High-grade T1 Bladder Cancer With Intravesical BCG vs Immediate Radical Cystectomy. Urology. 2024. PMID: 38467285. doi:10.1016/j.urology.2024.02.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。